Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.

Akimitsu MaedaKei IrieHitoshi AndoAyako HasegawaHiroya TaniguchiShigenori KadowakiKei MuroMasahiro TajikaMasahiro AokiKazuhide InagumaMasaki KajitaAkio FujimuraShoji Fukushima

Published in: Cancer chemotherapy and pharmacology (2018)

Regorafenib concentrations were associated with total bilirubin elevation and thrombocytopenia. Total serum bilirubin could be a useful marker when estimating regorafenib pharmacokinetics.

Keyphrases

metastatic colorectal cancer
early onset
drug induced
adverse drug
electronic health record